GSK Invests £25 Million into their Montrose, Scotland Facility
GSK Invests £25 Million into their Montrose, Scotland FacilityGlaxoSmithKline (GSK) have announced that they will invest £25 million to bring production of ingredients for four new pharmaceutical products to their site in Montrose, Scotland.
The investment is expected to create 25 new jobs for process technicians, engineers and chemists, increasing the total GlaxoSmithKline workforce in Scotland to over 750 employees. 50 contractors will also be employed during the construction phase of the expansion.
GSK have not revealed any specifics regarding which drugs will be manufactured at Montrose, however a spokesman informed PharmaTimes that the drugs will be in the respiratory and oncology areas. Presently, older respiratory drugs are produced at the Monstrose site, in addition to HIV/AIDS treatments.
The expansion comes on top of GSK’s pledge in 2012 to invest £100 million in Montrose and their other Scottish manufacturing site in Irvine, which produces antibiotics. The Scottish government noted that in recent years, GlaxoSmithKline has also invested around £40 million “in bringing technology and capability to Scotland that was previously undertaken overseas.”
Roger Connor, president of global manufacturing and supply at the GSK, commented that the “teams in Montrose and Irvine are world class and have worked hard to bring new facilities to the two sites,” adding that the Montrose site “will work alongside our sister site in Singapore to meet international demand for some of the world’s most important medicines.”
GlaxoSmithKline is the largest pharmaceutical company in Scotland in terms of employment and investment, contributing £80 million annually to the country’s economy.